Kim, Joon-Tae http://orcid.org/0000-0003-4028-8339
Lee, Ji Sung
Kim, Beom Joon
Park, Jong-Moo
Kang, Kyusik
Lee, Soo Joo
Kim, Jae Guk
Cha, Jae-Kwan
Kim, Dae-Hyun
Park, Tai Hwan
Park, Sang-Soon
Lee, Kyung Bok
Lee, Jun
Hong, Keun-Sik
Cho, Yong-Jin
Park, Hong-Kyun
Lee, Byung-Chul
Yu, Kyung-Ho
Oh, Mi Sun
Kim, Dong-Eog
Ryu, Wi-Sun
Choi, Jay Chol
Kwon, Jee-Hyun
Kim, Wook-Joo
Shin, Dong-Ick
Sohn, Sung Il
Hong, Jeong-Ho
Park, Man-Seok
Choi, Kang-Ho
Cho, Ki-Hyun
Lee, Juneyoung
Gorelick, Philip B.
Bae, Hee-Joon
Funding for this research was provided by:
Research of Korea Centers for Disease Control and Prevention (2017ER620101#)
Article History
Received: 30 January 2020
Revised: 10 May 2020
Accepted: 13 May 2020
First Online: 29 May 2020
Compliance with Ethical Standards
:
: The authors declare that they have no conflicts of interest.
: H.-J.B is involved in the principal investigation, a member of the steering committee, and/or a site investigator of multicenter clinical trials or clinical studies sponsored by Otsuka Korea, Bayer, Boehringer Ingelheim, Handok Pharmaceutical Company, SK Chemicals, Pfizer, ESAI-Korea, Daewoong Pharmaceutical Co. Ltd., Daiichi Sankyo, AstraZeneca Korea, Dong-A Pharmaceutical, Yuhan Corporation, BMS Korea, Korean Drug Co., Ltd., Servier, Shire Korea Ltd., and Shin Poong Pharm. Co. Ltd.; served on the scientific advisory board for Amgen Asia Holding Limited; served as the consultant for Celltrion, Inc. and Korean Drug Co., Ltd.; and received lecture honoraria from Daiichi Sankyo Korea, Otsuka Korea, Esai Korea, Korean Drug Co., Ltd., and Shire Korea Ltd. (modest). PBG serves as a member of the ARRIVE Steering Committee for Bayer (modest).
: The current study was approved by the local institutional review boards at all participating centers, including the Chonnam National University Hospital.
: The requirement for a written informed consent from the study subjects was waived based on maintenance of study subject anonymity and minimal risk to the participants.
: Not applicable.
: Not applicable.